Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Apr 6;9(10):2281-2288.
doi: 10.12998/wjcc.v9.i10.2281.

Recurrent undifferentiated embryonal sarcoma of the liver in adult patient treated by pembrolizumab: A case report

Xiao-He Yu  1 , Jian Huang  1 , Nai-Jian Ge  1 , Ye-Fa Yang  1 , Jin-Yan Zhao  2
Affiliations
Case Reports

Recurrent undifferentiated embryonal sarcoma of the liver in adult patient treated by pembrolizumab: A case report

Xiao-He Yu et al. World J Clin Cases. .

Abstract

Background: Undifferentiated embryonal sarcoma of the liver (UESL) is a neoplasm that rarely develops in adults. The main treatments for UESL are upfront gross total surgical resection and adjuvant multiagent chemotherapy. Here, we report a case of recurrent UESL in an adult treated with pembrolizumab and discuss a method to identify proper candidates for antibody of programmed cell death protein 1 (anti-PD-1) treatment.

Case summary: A 69-year-old woman was admitted for abdominal pain that developed for 1 wk. Computed tomography showed a 16 cm mass in the right lobe of the liver. Right hemihepatectomy and lymphadenectomy were performed, and histological diagnosis was UESL. Six months later, the patient suffered from painless obstructive jaundice, and positron emission tomography-computed tomography revealed multiple metastases. Then, percutaneous transhepatic cholangial drainage was applied to reduce jaundice, and radiofrequency ablation was used to control the lesion near the hepatic hilum. However, the patient suffered from a serious fever caused by the tumor. The patient received treatment with pembrolizumab, and the prescribed dosage was 2 mg/kg every 3 wk. After the seventh dose, positron emission tomography-computed tomography revealed that the multiple metastases had nearly disappeared. Radiologic exam was used to evaluate the disease state, and no new lesions were found. Next-generation sequencing and immunohistology were applied to determine the reason why the patient had such a favorable response to pembrolizumab. Tumor mutation burden, microsatellite instability, and programmed death ligand 1 expression can be combined to predict the effect of PD-1 antibodies. When every one of these biomarkers are detected in a tumor patient, the patient may be a proper candidate for PD-1 antibodies.

Conclusion: Anti-PD-1 treatment for tumors needs further research to identify indications and proper biomarkers.

Keywords: Case report; Immunohistology; Pembrolizumab; Programmed cell death protein 1; Tumor mutation burden; Undifferentiated embryonal sarcoma of the liver.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declared that they have no conflicts of interest regarding this work.

Figures

Figure 1
Figure 1
Timeline of the case. PET-CT: Positron emission tomography-computed tomography; PTCD: Percutaneous transhepatic cholangial drainage.
Figure 2
Figure 2
Positron emission tomography-computed tomography. A-C: Radioactive concentration of 18F-fluorodeoxyglucose on the tumor rim, and no radioactive concentration was observed in other areas of the body.
Figure 3
Figure 3
Positron emission tomography-computed tomography. A-D: Multiple metastases located in the liver, mediastinum and peritoneum.
Figure 4
Figure 4
Positron emission tomography-computed tomography. A-C: Multiple metastases had nearly disappeared.
Figure 5
Figure 5
Immunohistological staining. A-D: There was high expression of CD8, low expression of CD4 and little expression of CD68 in the tumor. Up to 90% of tumor cells expressed programmed death ligand 1 (PD-L1).
See this image and copyright information in PMC

References

    1. Stocker JT, Ishak KG. Undifferentiated (embryonal) sarcoma of the liver: report of 31 cases. Cancer. 1978;42:336–348. - PubMed
    1. Esteban SG, Emilio CU, Emmanuel AF, Oscar SJ, Paulina CE, Angel MM. Undifferentiated embryonal sarcoma of the liver in adult patient: A report of two cases. Ann Hepatobiliary Pancreat Surg. 2018;22:269–273. - PMC - PubMed
    1. Techavichit P, Masand PM, Himes RW, Abbas R, Goss JA, Vasudevan SA, Finegold MJ, Heczey A. Undifferentiated Embryonal Sarcoma of the Liver (UESL): A Single-Center Experience and Review of the Literature. J Pediatr Hematol Oncol. 2016;38:261–268. - PubMed
    1. Ohnishi T, Yasuda I, Nishigaki Y, Hayashi H, Otsuji K, Mukai T, Enya M, Omar S, Soehendra N, Tomita E, Moriwaki H. Intraductal chilled saline perfusion to prevent bile duct injury during percutaneous radiofrequency ablation for hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23:e410–e415. - PubMed
    1. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–413. - PMC - PubMed

Publication types